Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cyclerion Therapeutics, Inc.    CYCN

CYCLERION THERAPEUTICS, INC.

(CYCN)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
2.99(c) 3.115(c) 2.98(c) 3.23(c) 3.26(c) Last
372 243 732 254 974 321 717 279 399 248 Volume
-0.99% +4.18% -4.33% +8.39% +0.93% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -83,0 M - -
Net cash position 2020 51,0 M - -
P/E ratio 2020 -1,99x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -43,0 M - -
Net cash position 2021 109 M - -
P/E ratio 2021 -11,6x
Yield 2021 -
Capitalization 111 M 111 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 94
Free-Float 85,0%
More Financials
Company
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily... 
More about the company
All news about CYCLERION THERAPEUTICS, INC.
11/05CYCLERION THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
AQ
11/05CYCLERION THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Recent..
AQ
11/05Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recen..
GL
10/15CYCLERION THERAPEUTICS : Announces Phase 2 STRONG-SCD Study Results in Patients ..
AQ
10/15CYCLERION THERAPEUTICS : Announces Positive Data from IW-6463 CNS Translational ..
AQ
10/14CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
10/14CYCLERION THERAPEUTICS : Announces Phase 2 STRONG-SCD Study Results in Patients ..
AQ
10/14CYCLERION THERAPEUTICS : Announces Positive Data from IW-6463 CNS Translational ..
AQ
10/14Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle ..
GL
10/14Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology..
GL
10/01CYCLERION THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
09/04Cyclerion to Participate at Upcoming September 2020 Investor Conferences
GL
09/03CYCLERION THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Finan..
AQ
08/26CYCLERION THERAPEUTICS : Announces Translational Research Award from the Alzheim..
AQ
08/25Cyclerion Announces Translational Research Award from the Alzheimer's Associa..
GL
More news
News in other languages on CYCLERION THERAPEUTICS, INC.

- No features available -

More news
Chart CYCLERION THERAPEUTICS, INC.
Duration : Period :
Cyclerion Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYCLERION THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 4,00 $
Last Close Price 3,26 $
Spread / Highest target 22,7%
Spread / Average Target 22,7%
Spread / Lowest Target 22,7%
EPS Revisions
Managers
NameTitle
Peter M. Hecht Chief Executive Officer & Director
Mark G. Currie President & Chief Scientific Officer
Marsha H. Fanucci Chairman
William I. Huyett Chief Financial Officer
Christopher I. Wright Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CYCLERION THERAPEUTICS, INC.19.85%111
IQVIA HOLDINGS INC.9.26%32 365
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
PRA HEALTH SCIENCES, INC.-0.14%7 120
SYNEOS HEALTH, INC.12.08%6 932
NOVAVAX, INC.2,477.89%6 427